title: Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease.
abstract: Changes of hemostatic parameters during percutaneous transluminal coronary angioplasty (PTCA) in 75 patients with chronic coronary artery disease were evaluated. Plasma levels of D-dimer, soluble fibrin monomer, plasmin-alpha2 antiplasmin inhibitor complex, and tissue factor (TF) were significantly increased in all patients with chronic coronary artery disease. The activity of antithrombin and protein C and the levels of protein C antigen were significantly decreased 1 hr after PTCA, but they returned to normal range 1 day after PTCA. There was no significant difference in the level of plasma APC-PCI complex before and 1 hr after PTCA. The plasma levels of D-dimer, soluble fibrin monomer, thrombomodulin, TF and PPIC were significantly decreased 1 hr, and the plasma levels of plasmin-alpha2 antiplasmin inhibitor complex 1 day after PTCA. These findings suggest that the decrease of protein C and antithrombin resulted in activation of the coagulation system. One hour after PTCA, the plasma levels of (total-free) TF pathway inhibitor (TFPI) were significantly decreased, but the plasma levels of total and free-TFPI were significantly increased, suggesting that consumption of (total-free) TFPI occurs during PTCA. Overall, these findings suggest that the hypercoagulable state improves during PTCA and that transient decrease of antithrombin, protein C, (total-free) TFPI or plasmin-alpha2 antiplasmin inhibitor complex may cause restenosis of coronary artery.
authors.affiliation: First Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie-ken, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: M
authors.initials: M
authors.lastname: Yamamuro
authors.forename: A
authors.initials: A
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Shimura
authors.forename: K
authors.initials: K
authors.lastname: Hiyoyama
authors.forename: E C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: N
authors.initials: N
authors.lastname: Isaka
authors.forename: H
authors.initials: H
authors.lastname: Shiku
authors.forename: H
authors.initials: H
authors.lastname: Takeya
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Kumeda
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Nakano
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D001779:Blood Coagulation Factors / Q000378:metabolism; D002908:Chronic Disease; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000378:metabolism; D011740:Pyrimidine Dimers / Q000097:blood*; D015842:Serine Proteinase Inhibitors / Q000097:blood*; D013925:Thromboplastin / Q000378:metabolism*; D000979:alpha-2-Antiplasmin / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D001779:Blood Coagulation Factors; D008074:Lipoproteins; D011486:Protein C; D011740:Pyrimidine Dimers; D015842:Serine Proteinase Inhibitors; D000979:alpha-2-Antiplasmin; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin